Literature DB >> 3490761

Expandable intrahepatic portacaval shunt stents in dogs with chronic portal hypertension.

J C Palmaz, F Garcia, R R Sibbitt, F O Tio, D T Kopp, W Schwesinger, J L Lancaster, P Chang.   

Abstract

A canine experimental model was used to investigate the feasibility of using balloon-expandable portacaval shunts in humans with chronic portal hypertension. Intrahepatic portacaval shunts were created in nine dogs with stable portal hypertension previously induced by intraportal injections of polyvinyl alcohol (Ivalon). Embolic material was injected periodically through a subcutaneous port that allowed repeated access to the portal system. Shunts were placed 14 weeks after the last embolization. A shunt patency rate of 100% was observed up to 48 weeks. Low portacaval pressure gradient and high shunt flow accounted for the good results.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490761     DOI: 10.2214/ajr.147.6.1251

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

1.  Historical overview on the development and characteristics of stents and future outlooks.

Authors:  C L Zollikofer; F Antonucci; G Stuckmann; P Mattias; E K Salomonowitz
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

2.  Transjugular intrahepatic portocaval shunt (TIPS) and hepatic vein-to-caval stenting as salvage treatment of portal hypertension secondary to neoplasm.

Authors:  R P Davies; G R Sissons; N A McIntosh
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Mar-Apr       Impact factor: 2.740

3.  Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy.

Authors:  J Wiltfang; W Nolte; M Otto; J Wildberg; E Bahn; H R Figulla; L Pralle; H Hartmann; E Rüther; G Ramadori
Journal:  Metab Brain Dis       Date:  1999-12       Impact factor: 3.584

Review 4.  Current status and future possibilities of transjugular intrahepatic portosystemic shunts in the management of portal hypertension.

Authors:  P M Radosevich; J M LaBerge; R L Gordon
Journal:  World J Surg       Date:  1994 Sep-Oct       Impact factor: 3.352

Review 5.  Interventional treatment of hepatic arterial and venous pathology: a commentary.

Authors:  J Rösch; B D Petersen; L D Hall; K Ivancev
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

6.  The transjugular intrahepatic portosystemic stent-shunt (TIPSS): results of a pilot study.

Authors:  G M Richter; G Noeldge; J C Palmaz; M Roessle
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

7.  On the implementation of an automated acoustic output optimization algorithm for subharmonic aided pressure estimation.

Authors:  J K Dave; V G Halldorsdottir; J R Eisenbrey; D A Merton; J B Liu; P Machado; H Zhao; S Park; S Dianis; C L Chalek; K E Thomenius; D B Brown; F Forsberg
Journal:  Ultrasonics       Date:  2013-01-02       Impact factor: 2.890

8.  Transjugular intrahepatic portasystemic stent shunting for control of acute and recurrent upper gastrointestinal haemorrhage related to portal hypertension.

Authors:  K J Simpson; N Chalmers; D N Redhead; N D Finlayson; I A Bouchier; P C Hayes
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

9.  Morphologic and clinical results of the transjugular intrahepatic portosystemic stent-shunt (TIPSS).

Authors:  G Noeldge; G M Richter; M Roessle; K Haag; B T Katzen; G J Becker; J C Palmaz
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

10.  Investigating the efficacy of subharmonic aided pressure estimation for portal vein pressures and portal hypertension monitoring.

Authors:  Jaydev K Dave; Valgerdur G Halldorsdottir; John R Eisenbrey; Daniel A Merton; Ji-Bin Liu; Jian-Hua Zhou; Hsin-Kai Wang; Suhyun Park; Scott Dianis; Carl L Chalek; Feng Lin; Kai E Thomenius; Daniel B Brown; Flemming Forsberg
Journal:  Ultrasound Med Biol       Date:  2012-08-21       Impact factor: 2.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.